Furosemide - Cutanea Life Sciences

Drug Profile

Furosemide - Cutanea Life Sciences

Alternative Names: CLS 006

Latest Information Update: 21 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cutanea Life Sciences
  • Class Antihypertensives; Heart failure therapies; Small molecules; Sulfanilamides
  • Mechanism of Action Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Warts

Most Recent Events

  • 01 Sep 2017 Phase-III clinical trials in Warts (In children) in USA (Topical) (NCT03259620)
  • 01 Sep 2017 Cutanea Life Sciences initiates enrolment in a phase III trial in Warts (In adolescents, In adults, In the elderly) in USA (Topical) (NCT03259620)
  • 30 Aug 2017 Cutanea Life Sciences plans a phase III trial for Warts (In children, In adolescents, In adults, In elderly) (NCT03259620)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top